Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

NCT04327037 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Acute Myeloid
Leukemia, Acute Lymphoblastic

Interventions

BIOLOGICAL: Expanded Haploidentical Natural Killer cells
DRUG: IL-2

Sponsor

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology